EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

Inclusion criteria:

• Male or female patient age >= 18 years at screening. For Japan only: Age >= 20 yearsat screening
• Patients with chronic HF (Chronic Heart Failure) NYHA (New York Heart AssociationClassification) class II-IV and reduced EF (Ejection Fraction) (LVEF (Left VentricularEjection Fraction) <=40%) and elevated NT-proBNP (N-terminal of the prohormone brainnatriuretic peptide)
• If EF >= 36% to <= 40%: NT-proBNP >= 2500 pg/ml or patients without AF (atrialfibrillation/atrial flutter) and NT-proBNP >= 5000 pg/ml for patients with AF
• If EF >= 31% to <= 35%: NT-proBNP >= 1000 pg/ml for patients without AF andNT-proBNP >=2000 pg/ml for patients with AF
• If EF<= 30%: NT-proBNP >= 600 pg/ml for patients without AF and NT-proBNP >=1200pg/ml for patients with AF
• EF ≤ 40% and hospitalization for heart failure in the past 12 months: NTproBNP ≥ 600 pg/ml for patients without AF and NT-proBNP >= 1200 pg/ml for patients withAF
• Appropriate dose of medical therapy for HF consistent with prevailing local andinternational CV (Cardiovascular) guidelines, stable for at least 1 week prior toVisit 1
• Appropriate use of medical devices such as cardioverter defibrillator (ICD) or acardiac resynchronization therapy (CRT) consistent with prevailing local orinternational CV guidelines
• Signed and dated written ICF (Informed Consent Form)
• Further inclusion criteria apply

Exclusion criteria:

• Myocardial infarction, coronary artery bypass graft surgery, or other majorcardiovascular surgery, stroke or TIA (Transient Ischaemic Attack) in past 90 daysprior to Visit 1
• Heart transplant recipient, or listed for heart transplant
• Acute decompensated HF
• Systolic blood pressure (SBP) >= 180 mmHg at Visit 2.
• Symptomatic hypotension and/or a SBP < 100 mmHg
• Indication of liver disease
• Impaired renal function, defined as eGFR (Estimated Glomerular Filtration Rate) < 20mL/min/1.73 m2 (CKD-EPI (Chronic Kidney Disease - Epidemiology CollaborationEquation)) or requiring dialysis
• History of ketoacidosis
• Current use or prior use of a SGLT (Sodium-glucose co-transporter)-2 inhibitor orcombined SGLT-1 and 2 inhibitor
• Currently enrolled in another investigational device or drug study
• Known allergy or hypersensitivity to empagliflozin or other SGLT-2 inhibitors
• Women who are pregnant, nursing, or who plan to become pregnant while in the trial
• Further exclusion criteria apply